A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
Latest Information Update: 29 May 2024
At a glance
- Drugs NBI 921352 (Primary) ; NBI 921352 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
Most Recent Events
- 29 May 2024 This study has been Discontinued in Portugal, According to European Clinical Trials Database record.
- 20 May 2024 Planned End Date changed from 1 May 2026 to 1 Mar 2026.
- 04 Feb 2024 This trial has been discontinued in Italy.